Loading clinical trials...

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma | Clinical Trials | Clareo Health

TERMINATEDPHASE1

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

A Single-arm, Open-label Clinical Study to Assess the Safety and Efficacy of the C752 CAR-T Cells for Patients With CD19+ Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

NCT06210243•920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

View on ClinicalTrials.gov

Summary

It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Written informed consent in accordance with federal, local, and institutional guidelines, Males and females ≥18 years of age at the time of consent
•Documented diagnosis of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
•Have progression by least one systemic treatment and no available standard of care treatment.
•At least one measurable lesion by Lugano 2014
•Expected survival ≥ 12 weeks
•Have an ECOG performance status of 0 or 1
•Adequate organ function
•Screening test indicates histopathological CD19 + if the subject received CD19-targeted therapy
•Women of childbearing age must have a negative pregnancy test, and agree to take effective contraception during the trial

Exclusion Criteria

•Treatment with any prior HSCT, gene therapy product, cell therapy product ect.
•Central nervous system involvement
•HBV/HCV
•HIV infection
•Concurrent use of systemic steroids or immunosuppression
•Uncontrolled active infection
•Wash-out period of from the last anti-cancer treatment
•Active second malignancy
•Have not recovered from the effects of previous therapy
•Have psychological or physical conditions that do not permit compliance with the protocol
+1 more criteria

Locations (1)

920th Hospital of Joint LogisticsSupport Force of People's Liberation

Kunming, Yunnan, China

Key Dates

Start Date

December 24, 2023

Primary Completion Date

December 24, 2024

Completion Date

December 24, 2024

Last Updated

February 18, 2025

Enrollment

ACTUAL participants

Conditions

Lymphoma, B-CellCAR-T

Interventions

C752

BIOLOGICAL

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT04161248

Lymphoma, B-Cell

View study

RECRUITINGPHASE1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

NCT06528301

Lymphoma, B-CellLymphoma, Non-Hodgkin (NHL)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Inclusion Criteria

Exclusion Criteria

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas